Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-PCSSC pilot study in homozygous familial hypercholesterolemia
NL-OMON45636Phase 2Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Feb 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inclisiran in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, sponsored by The Medicines Company. Primary endpoints: Percentage change in LDL-C from Day 1 at Day 90 and Percentage change in LDL-C from Day 1 at Day 180. Started Feb 2018; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON45636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45636.